ArticleFrontiers in oncology2025
Quality of life, fatigue, and muscle strength in women with breast cancer undergoing chemotherapy or hormonal therapy: a case-control study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer treatments negatively affect women's physical and emotional well-being due to adverse effects. This study compared the quality of life, fatigue levels, and muscle strength of women with breast cancer undergoing chemotherapy or hormonal therapy with a control group of healthy women. Methods: A case-control study was conducted including women aged 45 to 65 years diagnosed with breast cancer between October 2021 and August 2022 at the Hospital das Clínicas de Goiânia, Brazil. Approximately one age-matched control was selected from the general population for every 2.2 cases. Quality of life was assessed using the EORTC QLQ-BR23, fatigue with the FACT B + 4, and muscle strength through handgrip tests. Results: Ninety-five participants were included (65 cases, 30 controls). Among cases, 40% (n = 26) were undergoing chemotherapy and 60% (n = 39) hormonal therapy. Quality-of-life domains such as general symptoms, side effects, and arm and chest symptoms were worse among treated cases compared to controls (p < 0.01 for all). No significant differences were observed between treatment groups (p > 0.05). Fatigue levels were higher among cases compared to controls in domains such as physical and social well-being, general fatigue, cancer- related fatigue, and breast cancer-related fatigue (p < 0.01, p = 0.05, p < 0.01, p < 0.01, p < 0.01, respectively), with no significant differences between treatment groups (p > 0.05). Handgrip strength was lower in cases treated with hormonal therapy on the right side compared to controls (-5.0; 95% CI: -7.69 to -2.31; effect size: -0.49) which represents a moderate magnitude effect. On the left side, both treatment groups showed reduced strength compared to controls (-5.1; 95% CI: -7.99 to -2.21; -5.9; 95% CI: -8.51 to -3.29; effect sizes: -0.93 and -1.04, respectively) indicating effects of large magnitude, which may suggest possible clinical relevance. No significant differences were observed between treatment groups (p > 0.05). Conclusion: Differences in quality of life, fatigue, and muscle strength were observed between women undergoing treatment and those who were healthy, with no distinction between types of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.